Enhancement of in vitro binding and some of the pharmacological properties of diazepam by a novel anthelmintic agent, Avermectin B1a.
A novel macrocyclic lactone disaccharide anthelmintic agent, Avermectin B1a (AVM) has been found to cause a concentration-dependent increase in the in vitro binding of 3H-diazepam to rat and mouse brain membranes. The increase in binding is manifested as both an increase in the affinity and number of bindings sites for 3H-diazepam. Preliminary in vivo studies demonstrate that AVM can also enhance some of the pharmacological actions of diazepam.
D000818:Animals; D000871:Anthelmintics / Q000494:pharmacology*; D001665:Binding Sites / Q000187:drug effects; D003975:Diazepam / Q000494:pharmacology*; D004187:Disaccharides / Q000494:pharmacology; D005260:Female; D007559:Ivermectin / Q000031:analogs & derivatives; D007783:Lactones / Q000494:pharmacology*; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D051381:Rats; D013570:Synaptic Membranes / Q000187:drug effects
D000871:Anthelmintics; D004187:Disaccharides; D007783:Lactones; D007559:Ivermectin; C019264:avermectin; D003975:Diazepam